VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Summary

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Head and Neck Carcinoma
• Adenoid Cystic Carcinoma
• Lung Cancer
• Non-Small Cell Lung Cancer
• Pancreatic Cancer
• Mesothelioma
• Esophageal Cancer
• Any Solid Tumors Progressed After a Prior Immunotherapy
• Head and Neck Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma HNSCC
• Salivary Gland Carcinomas
• Head and Neck Cancers - Salivary Gland
• Head and Neck Cancers - Nasopharyngeal
• Head and Neck Cancers - Throat
• Small Cell Lung Cancer ( SCLC )
• Lung Cancer (Locally Advanced or Metastatic)
• Head and Neck Cancers - Tonsils
• Head and Neck Cancers Hypopharynx
• Head and Neck Cancers Larynx
• Head and Neck Cancers Lip
• Head and Neck Cancers Nasopharynx
• Head and Neck Cancers Oral Cavity
• Head and Neck Cancers
• Head and Neck Cancers Oropharynx
• Head and Neck Cancers Trachea

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

VM Oncology, LLC

Last updated on ClinicalTrials.gov

December 11, 2025

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites